The project, which could cost up to $500 billion, was described by Trump as the "largest AI infrastructure project in history ...

As of January 31 at 3:58:55 PM EST. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The researchers obtained demographic data, medical history, and hospital records of ... of which 95% had received the Pfizer-BioNTech mRNA vaccine. In comparison, the remaining 5% had received ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

But scientists at Moderna are in the late stages of testing what could be the first such shot, using mRNA technology against the virus. Here’s what to know about norovirus and where things stand ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $60.0 for Moderna over the recent three months. Looking at the volume ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...